Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemited: cemiplimab plus TEDOPI maintenance in ctDNA-positive NSCLC
2024-519262-42-00Phase 2Authorised
- Sponsor
- Fondazione Ricerca Traslazionale
- Start
- Jul 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of cemiplimab, Tedopi and pemetrexed in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Fondazione Ricerca Traslazionale. Primary endpoint: ctDNA clearance rate. Planned start Jul 2025; status: authorised.
02
Drugs
cemiplimabTedopipemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-519262-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519262-42-00.